Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sitagliptin/Metformin XR in Healthy Chinese Subjects
NCT07679711Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Feb 2023; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07679711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679711.